Funded in part by Amgen, Sanofi, Alexion Pharmaceuticals, DSM Nutritional Products, UCB Pharma, Abiogen Pharma
Consensus Statement on Vitamin D Status Assessment and Supplementation: Whys, Whens, and Hows
Giustina A, Bilezikian JP, Adler RA, Banfi G, Bikle DD, Binkley NC, Bollerslev J, Bouillon R, Brandi ML, Casanueva FF, di Filippo L, Donini LM, Ebeling PR, Fuleihan GE, Fassio A, Frara S, Jones G, Marcocci C, Martineau AR, Minisola S, Napoli N, Procopio M, Rizzoli R, Schafer AL, Sempos CT, Ulivieri FM, Virtanen JK
Endocrine reviews · 275 citations
Review labels
Neutral facts our review recorded about how this study was done. They describe method, never whether we like the result.
How it was studied
- Design
- Expert or government fact sheet (classified by our AI screen)
- Main outcome
- Clinical events such as disease or death
Who paid for it
- Funding
- Industry funded
- Company
- Amgen
- Company
- Sanofi
- Company
- Alexion Pharmaceuticals
- University or hospital
- Oregon State University
- Nonprofit
- Barts Charity
- Government
- National Institute for Health and Care Research
- Company
- DSM Nutritional Products
- Government
- National Institute of Arthritis and Musculoskeletal and Skin Diseases
- Company
- UCB Pharma
- Government
- NIAMS NIH HHS
- Company
- Abiogen Pharma
- Authors
- At least one author declares a financial tie to industry
- Grants
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (P30AR075055)
Based on 11 listed funder(s) and full-text disclosure statement.
Publication
- Published
- 2024-04-27 · Endocr Rev · vol. 45 · issue 5 · pp. 625–654
- Publisher
- Oxford University Press
- Cited
- 349 citations · more than 100% of similar papers · 98.0× the field average
- Impact
- Top 10% most cited in its field
- References
- 282 works
- Access
- Open access (hybrid journal) · CC-BY
- Research areas
- Vitamin D Research Studies · Vitamin C and Antioxidants Research · Bone health and osteoporosis research
- Keywords
- Vitamin D and neurology, Medicine, Clinical trial, Cholecalciferol, Osteomalacia, Vitamin, Diabetes mellitus, vitamin D deficiency, Intensive care medicine, Internal medicine, Physiology, Endocrinology
- MeSH
- humans, vitamin d deficiency, vitamin d, dietary supplements, review literature as topic
27 authors
From IT, US, NO, BE, ES, AU, LB, CA, GB, CH, FI
- Andrea GiustinaVita-Salute San Raffaele University
- John Paul Bilezikian · corresponding
- Robert A. AdlerVirginia Commonwealth University
- Giuseppe BanfiVita-Salute San Raffaele University; Istituto Clinico Sant'Ambrogio
- Daniel D. BikleSan Francisco VA Medical Center
- Neil BinkleyUniversity of Wisconsin–Madison
Abstract
The 6th International Conference, "Controversies in Vitamin D," was convened to discuss controversial topics, such as vitamin D metabolism, assessment, actions, and supplementation. Novel insights into vitamin D mechanisms of action suggest links with conditions that do not depend only on reduced solar exposure or diet intake and that can be detected with distinctive noncanonical vitamin D metabolites. Optimal 25-hydroxyvitamin D (25(OH)D) levels remain debated. Varying recommendations from different societies arise from evaluating different clinical or public health approaches. The lack of assay standardization also poses challenges in interpreting data from available studies, hindering rational data pooling and meta-analyses. Beyond the well-known skeletal features, interest in vitamin D's extraskeletal effects has led to clinical trials on cancer, cardiovascular risk, respiratory effects, autoimmune diseases, diabetes, and mortality. The initial negative results are likely due to enrollment of vitamin D-replete individuals. Subsequent post hoc analyses have suggested, nevertheless, potential benefits in reducing cancer incidence, autoimmune diseases, cardiovascular events, and diabetes. Oral administration of vitamin D is the preferred route. Parenteral administration is reserved for specific clinical situations. Cholecalciferol is favored due to safety and minimal monitoring requirements. Calcifediol may be used in certain conditions, while calcitriol should be limited to specific disorders in which the active metabolite is not readily produced in vivo. Further studies are needed to investigate vitamin D effects in relation to the different recommended 25(OH)D levels and the efficacy of the different supplementary formulations in achieving biochemical and clinical outcomes within the multifaced skeletal and extraskeletal potential effects of vitamin D.
Abstract via Europe PMC. Copyright remains with the authors or publisher (CC BY).
Community trust
Loading…
How much do you trust this study's findings?
Comments
Sign in to rate, comment on or flag this study.Sign inSomething wrong here?
Flag this study if its information, labels or funding look wrong. An editor reviews every flag.
Sign in to rate, comment on or flag this study.Sign inEducational information about published research. Not medical advice, and not a recommendation to start or stop anything.